Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130841 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL13923572 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL8434237 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL13107064 | 0.93 | SMN1; SMN2 (0.54) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL125382 | 0.92 | — | — | |
| SCHEMBL14658202 | 0.92 | SMN1; SMN2 (0.58) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL127440 | 0.91 | ALDH1A1 (0.53) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL12656490 | 0.91 | ALDH1A1 (0.53) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL9406577 | 0.89 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 | |
| SCHEMBL9406952 | 0.89 | ALDH1A1 (0.48) | ALDH1A1TDP1SMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | ALDH1A1 580/4885TDP1 4125/4885SMN1; SMN2 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.